Bicara Therapeutics Inc. (BCAX)
NasdaqGM · USD · Healthcare · Biotechnology
$16.85 (-0.25%) as of
Key statistics
- Market cap
- 1.11B
- Forward P/E
- -4.78
- EPS (TTM)
- -3.08
- Dividend yield
- 0.00%
- 52-week range
- 13.70 – 30.99
- Beta
- -0.69
- Profit margin
- 0.00%
- Analyst target
- $35.67
- Volume
- 14.54k
About Bicara Therapeutics Inc.
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Boston, MA, United States
- Employees
- 103
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.